<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02210299</url>
  </required_header>
  <id_info>
    <org_study_id>35RC13_8917_TEXTO</org_study_id>
    <secondary_id>2014-A00782-45</secondary_id>
    <secondary_id>14/25-941</secondary_id>
    <secondary_id>140682B-82</secondary_id>
    <nct_id>NCT02210299</nct_id>
  </id_info>
  <brief_title>TEXTO : Total EXposure To Organic Pollutants</brief_title>
  <acronym>TEXTO</acronym>
  <official_title>TEXTO : Total EXposure To Organic Pollutants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherche en Santé, Environnement et le Travail, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire d'Etude des Résidus et Contaminants dans les Aliments</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de l'Environnement Industriel et des Risques</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Agency for Sanitary Safety of the Food of the Environment and Labor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People are, especially in industrialized countries, exposed to a growing number of ubiquitous&#xD;
      chemical substances. It thus increases human exposure pathways: diet, inhalation, soil and&#xD;
      dust dermal contact…), notably for semi-volatile organic compounds. Diet is generally sought&#xD;
      to contribute the most to total exposure for many chemicals, the relative contribution of&#xD;
      each pathway is nevertheless poorly described, and can be different among populations. This&#xD;
      is in particularly the case For young children, who can be more exposed via the environment,&#xD;
      because of frequent contact with object and dust and hand to mouth behaviors. Children are in&#xD;
      addition considered more sensitive to chemical risk due to their maturating systems.&#xD;
&#xD;
      In this context, the objective of this project is to characterize the young children's&#xD;
      exposure to a particular class of semi volatile organic compounds. It will encompass the&#xD;
      relative contribution of different pathways to the external dose, and to try to match the&#xD;
      internal and external doses with a physiologically based pharmacokinetic (PBPK) model for&#xD;
      molecules for which it is possible.&#xD;
&#xD;
      The present demand concerns a feasibility study on 2 children, for Perfluorinated Alkylated&#xD;
      Substances (PFAS), used in numerous consumer products.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot study for testing feasibility of cross sectional integrative exposure study.&#xD;
&#xD;
      Strategy : Exposure assessment of young children to PFAS with simultaneous measurement of&#xD;
      internal (serum) and external doses (diet, indoor environment: contamination data and human&#xD;
      exposure factors; quantity ingested and breathed).&#xD;
&#xD;
      Expected outcomes :&#xD;
&#xD;
      Assessment of feasibility to obtain:&#xD;
&#xD;
        -  original data on children's body burden&#xD;
&#xD;
        -  original contamination data for food, water, air and dust ;&#xD;
&#xD;
        -  Matching of these data to identify main sources and pathways of exposure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled&#xD;
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility recruitment</measure>
    <time_frame>3 months</time_frame>
    <description>Main objective of this feasibility study is to set the scientific consortium to recruit and study 2 young children's exposures.&#xD;
Main judgement criteria : Effective enrolment of 2 young children during their consultation to Rennes hospital, from those having a blood sampling for medical purposes, and house survey.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protocol validation</measure>
    <time_frame>1 year</time_frame>
    <description>Second objective is to validate protocols, procedures and methods to study exposure to PFAS.&#xD;
Secondary judgment criteria :&#xD;
Possibility to sample an extra volume of blood, to prepare it and transport it at -18°C to Laberca lab, Nantes;&#xD;
Possibility to organize a home visit with sampling of diet, water, air, dust and delivery of dietary questionnaire;&#xD;
Possibility to quantify PFAS in dietary and environmental samples;&#xD;
Possibility to model the internal dose for some compounds from kinetics data, and to compare doses estimated from blood measurements to those from environmental and diet measurements</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Exposure study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2-6 months-old children and 12-18 months-old children</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure study</intervention_name>
    <description>Sampling of blood, food, water, air and dust and delivery of dietary questionnaire</description>
    <arm_group_label>Exposure study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Young children (2-6 months ; 12-18 months)&#xD;
&#xD;
          -  In outpatient pediatric or pediatric surgery ;&#xD;
&#xD;
          -  From their homes ;&#xD;
&#xD;
          -  With home located less than 30km from Rennes ;&#xD;
&#xD;
          -  Living at their home (not at childcare facility or child-minder);&#xD;
&#xD;
          -  With a scheduled blood sampling apart from this study ;&#xD;
&#xD;
          -  For child 2 - 6 months :&#xD;
&#xD;
          -  With diet exclusively based on milk (maternal exclusively or commercial exclusively)&#xD;
&#xD;
          -  In case of breastfeeding, with mother accepting milk sampling ;&#xD;
&#xD;
          -  With a free, enlightened and signed written consent from the parents.&#xD;
&#xD;
        Breastfeeding mother :&#xD;
&#xD;
          -  &gt; 18 years ;&#xD;
&#xD;
          -  Exclusive breastfeeding ;&#xD;
&#xD;
          -  With a free, enlightened and signed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Children :&#xD;
&#xD;
          -  Metabolic illness ;&#xD;
&#xD;
          -  Renal or hepatic insufficiency ;&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  With known HIV+, HBV+, HCV+, CMV+ serology&#xD;
&#xD;
          -  Simultaneously participating to other biomedical survey&#xD;
&#xD;
        For breastfeeding mother :&#xD;
&#xD;
          -  Under legal protection (judicial protection, guardianship) ;&#xD;
&#xD;
          -  mixed breastfeeding ;&#xD;
&#xD;
          -  with Known HIV+, HBV+, HCV+, CMV+ serology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Glorennec, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Inserm UMR 1085 - Institut de Recherche sur la Santé, l'Environnement et le Travail</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florence Rouget, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rennes Hospital University</name>
      <address>
        <city>Rennes</city>
        <state>Brittany</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2014</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy young children (2-6 months ; 12-18 months)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

